This year’s most-viewed articles and videos on myelodysplastic syndromes (MDS) explored patient quality of life, risk factors ...

Molecular data altered risk stratification for 30% of patients ... assessment of dysplasia and blast count in MDS, particularly in low blast cases and considering the wide clinical heterogeneity ...

Based Roundtable® event, Andrew M. Brunner, MD, discussed dosing strategy for erythropoiesis-stimulating agents as well as ...

The nature of immune dysregulation is markedly different between various MDS risk groups. In low-risk MDS, the immune system is in a proinflammatory state, whereas in high-risk disease ...

Refractory: when a disease does not respond to treatment. Cytopenias: low blood cell count. Anemia: low count of healthy red blood cells. "Lower-risk MDS affects a primarily elderly patient population ...

Most patients had MDS (39%), followed by CCUS (36%). In the evolution of myeloid subtype of blood cancers, the risk for cancer progressively increases with the mutation number, Venugopal explained ...

Myelodysplastic syndromes (MDS) with del(5q ... characterized by low or intermediate I International Prognostic Scoring System (IPSS) risk score were collected from nine centers and registries.

Thomas W. LeBlanc, MD, MA, discusses how the COMMANDS study, which compared luspatercept to epoetin alfa in erythropoiesis-stimulating agent (ESA)–naive, transfusion-dependent patients with low-risk ...

low or intermediate risk myelodysplastic syndromes (LR-MDS) without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for ...

"We are pleased that R289 has been granted Fast Track designation, which underscores the significant unmet need for patients with transfusion dependent lower-risk MDS," said Raul Rodriguez ...

Geron is seeking approval of imetelstat as a treatment for transfusion-dependent anemia in patients suffering from low-risk ...